EGFR-targeting RNase A-cetuximab antibody-drug conjugate induces ROS-mediated apoptosis to overcome drug resistance in KRAS mutant cancer cells
Abstract Antibody-drug conjugates (ADCs) are an emerging strategy in cancer therapy, enhancing precision and efficacy by linking targeted antibodies to potent cytotoxic agents. This study introduces a novel ADC that combines ribonuclease A (RNase A) with cetuximab (Cet), an anti-EGFR monoclonal anti...
Saved in:
Main Authors: | Bita Jafary, Mostafa Akbarzadeh-Khiavi, Hamed Farzi-Khajeh, Azam Safary, Khosro Adibkia |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-85856-9 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Leveraging RIBOTAC technology: Fluorescent RNase L probes for live-cell imaging and function analysis
by: Elias Khaskia, et al.
Published: (2025-01-01) -
Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01) -
Oxaliplatin-Loaded Chitosan Nanoparticles Decorated with Cetuximab Single-Chain Variable Fragment for Human Colorectal Cancer Treatment
by: Khadijeh Falahzadeh, et al.
Published: (2024-09-01) -
RNase P cleavage of pseudoknot substrates reveals differences in active site architecture that depend on residue N-1 in the 5’ leader
by: David M. Kosek, et al.
Published: (2025-12-01) -
Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
by: Wen-Chen Tang, et al.
Published: (2023-07-01)